New biosimilar for psoriasis enters human testing
NCT ID NCT07258745
First seen Dec 08, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tests a new biosimilar drug called CKD-704, which is similar to the approved psoriasis treatment Skyrizi. It involves 213 healthy adults who will receive a single dose of either CKD-704, EU-approved Skyrizi, or US-licensed Skyrizi. The goal is to compare how the drugs move through the body, their safety, and any immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MTZ powered by Pratia
RECRUITINGWarsaw, Warszawa, 02-172, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.